首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis.
【24h】

CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis.

机译:CCND1 G870A基因多态性与宫颈癌的风险:病例对照研究和荟萃分析。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Cyclin D1 (CCND1) is a key regulatory protein in the G1/S checkpoint of the cell cycle. We hypothesized that the G870A polymorphism of CCND1 is associated with the risk for cervical cancer and performed a meta-analysis of eligible studies to evaluate this relationship. METHODS: In a case-control study of 300 patients with newly diagnosed cervical cancer and 312 cancer-free controls who were frequency-matched by age, we genotyped the G870A polymorphism of CCND1 by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). A meta-analysis was performed using five case-control studies, including our results. RESULTS: No significant association was observed between the G870A polymorphism of CCND1 and cervical cancer risk. Further, in our meta-analysis, there was no significant risk of cervical cancer that correlated with the G870A polymorphism of CCND1. In the stratified analysis by race, however, individuals who harbored the AA or AA/AG genotypes were at significantly greater risk compared with GG carriers in the Asian population. CONCLUSION: The G870A polymorphism in CCND1 may not contribute to the etiology of cervical cancer in Chinese populations.
机译:目的:细胞周期蛋白D1(CCND1)是细胞周期G1 / S检查点的关键调节蛋白。我们假设CCND1的G870A多态性与宫颈癌的风险相关,并进行了符合条件的研究的荟萃分析,以评估这种关系。方法:在一项针对300名按年龄进行频率匹配的新诊断宫颈癌和312名无癌对照的病例对照研究中,我们通过聚合酶链反应限制性片段长度多态性(PCR-RFLP)对CCND1的G870A多态性进行了基因分型。 )。使用五项病例对照研究(包括我们的结果)进行了荟萃分析。结果:CCND1的G870A多态性与宫颈癌风险之间没有显着相关性。此外,在我们的荟萃分析中,没有与CCND1的G870A多态性相关的宫颈癌的显着风险。但是,在按种族进行的分层分析中,与亚洲人群中的GG携带者相比,具有AA或AA / AG基因型的个体的风险要高得多。结论:CCND1基因的G870A多态性可能与中国人群宫颈癌的病因无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号